未知生产厂商
CoronaVac, previously known as PiCoVacc, is a SARS-CoV-2 purified, inactivated, and adsorbed vaccine candidate developed by SinoVac Biotech Corporation. It was developed by propagating the SARS-CoV-2 CN2 strain inside Vero Cells and inactivating it with B-propiolactone. In preclinical trials, PiCoVacc induced SARS-CoV-2-specific neutralizing antibodies in rats, mice, and the rhesus macaque. The antibodies were found to neutralize 10 representative SARS-CoV-2 strains. As of August 2020, the vaccine is being tested in numerous human clinical trials assessing its safety and immunogenicity.
CoronaVac, previously known as PiCoVacc, is a SARS-CoV-2 purified, inactivated, and adsorbed vaccine candidate developed by SinoVac Biotech Corporation. It was developed by propagating the SARS-CoV-2 CN2 strain inside Vero Cells and inactivating it with B-propiolactone. In preclinical trials, PiCoVacc induced SARS-CoV-2-specific neutralizing antibodies in rats, mice, and the rhesus macaque. The antibodies were found to neutralize 10 representative SARS-CoV-2 strains. As of August 2020, the vaccine is being tested in numerous human clinical trials assessing its safety and immunogenicity.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
